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1
. Immortalized cancer cell lines, either cultured in vitro or grown as xenografts, cannot interrogate the complexity of human tumours and only provide determinate insights into human disease, as they are limited in number and diversity, and have been cultured on plastic over decades 2 . This disconnection in scale and biological accuracy contributes considerably to attrition in drug development [3] [4] [5] . effectively recapitulate the intra-tumour and inter-tumour heterogeneity that typifies human cancer [6] [7] [8] [9] . Exhaustive information on the key characteristics and the practical applications of PDXs can be found in recent reviews [10] [11] [12] [13] . In this Opinion article, we discuss basic methodological concepts, as well as challenges and opportunities in developing 'nextgeneration' models to improve the reach of PDXs as preclinical tools for in vivo studies (TABLE 1) . We also elaborate on the merits of PDXs for exploring the intrinsic heterogeneity and subclonal genetic evolution of individual tumours, and discuss how this may influence therapeutic resistance. Finally, we examine the utility of PDXs in navigating complex variables in clinical decision-making, such as the discovery of predictive and prognostic biomarkers, and the categorization of genotype-drug response correlations in high-throughput formats. Being primarily co-authored by leading members of the EurOPDX Consortium (see Further information), we provide a perspective on the value of PDX models as an important resource for the international cancer research community towards the realization of a precision medicine paradigm (BOX 1; TABLE 2).
Modelling cancer phenotypes
Interrogating intra-tumour heterogeneity and evolutionary dynamics. Cancer is increasingly being recognized as an ecosystem of cells that constantly evolves following Darwinian laws. Owing to cancer cell intrinsic mutability, an incipient tumour clone gives rise to a progeny of genetically heterogeneous subclones, some of which will thrive while others shrink, depending on their ability to cope with environmental selection pressures 14 . This is of particular relevance for cancer treatment, as most patients will eventually succumb to the disease owing to the appearance of resistant tumour subclones. Despite the considerable clinical impact of tumour heterogeneity 15 , little is known about how it affects response to cancer therapy and how it may change during treatment at both the genomic and the phenotypic levels [16] [17] [18] [19] [20] . These issues highlight the need for preclinical models that capture the heterogeneous nature of human cancers and their ongoing evolution.
Surgically derived clinical tumour samples that are implanted in mice (known as patient-derived xenografts (PDXs)) are expected to better inform therapeutic development strategies. As intact tissue -in which the tumour architecture and the relative proportion of cancer cells and stromal cells are both maintained -is directly implanted into recipient animals, the alignment with human disease is enhanced. More importantly, PDXs retain the idiosyncratic characteristics of different tumours from different patients; hence, they can Interrogating open issues in cancer precision medicine with patient-derived xenografts Abstract | Patient-derived xenografts (PDXs) have emerged as an important platform to elucidate new treatments and biomarkers in oncology. PDX models are used to address clinically relevant questions, including the contribution of tumour heterogeneity to therapeutic responsiveness, the patterns of cancer evolutionary dynamics during tumour progression and under drug pressure, and the mechanisms of resistance to treatment. The ability of PDX models to predict clinical outcomes is being improved through mouse humanization strategies and the implementation of co-clinical trials, within which patients and PDXs reciprocally inform therapeutic decisions. This Opinion article discusses aspects of PDX modelling that are relevant to these questions and highlights the merits of shared PDX resources to advance cancer medicine from the perspective of EurOPDX, an international initiative devoted to PDX-based research. For example, breast cancer is a constellation of at least 10 different genomic subtypes, each with distinct drivers and variable intra-tumour heterogeneity 15, 21, 22 . Recent evidence has suggested that each breast cancer comprises multiple tumour cell populations with distinct evolutionary trajectories that are likely to be affected by treatment pressure [23] [24] [25] . Genomic evolution between primary and recurrent tumours transcriptomic, epigenomic and histological levels, as well as in terms of shared signalling pathways 8, [30] [31] [32] . Notably, the majority of tumour subclones that change upon engraftment do not include known breast cancer oncogenic drivers 29 . This suggests that, although engraftment pressure is observed, it is evolutionarily neutral, as it does not affect intra-tumour heterogeneity when considering the clonal representation of relevant genes. These features probably underpin the successful use of breast cancer PDXs to predict clinical drug responses 9 and mechanisms of acquired resistance 33, 34 . As discussed below, an advantage of PDX models is that they can be generated with a limited amount of material; for example, using fine-needle biopsies (TABLE 1) . However, these methods may be confounding when the studied tumour type is particularly heterogeneous (such as melanoma). For example, within one tumour or metastasis, multiple melanoma subclones can exist, each harbouring different genetic and/or epigenetic alterations [35] [36] [37] . Simply taking a single biopsy sample can result in a PDX that does not represent the heterogeneity of the patient's tumour 35, 38 . Notably, regional genetic variability can be exacerbated by PDX serial propagation, producing divergent responses in tumour measurements within a single cohort of treated mice 32, 39 . Methods to overcome this limitation include good, standardized preclinical designs (those with adequate statistical power and proper randomization), as well as the mixing of heterogeneous tumour masses before implantation, such as through the use of single-cell suspension injections or rough tumour homogenates 24 . The direct derivation of PDXs from circulating tumour cells (CTCs) may represent another tool to further interrogate tumour heterogeneity. The numbers of cancer cells shed by tumours into the bloodstream may be exceedingly low, and the biological and clinical relevance of CTCs in sustaining malignant disease has been questioned 40 . However, as CTCs are shed by tumours on a stochastic rather than a deterministic basis 41 , they are expected to better recapitulate the distribution of different subclonal tumour populations (TABLE 1) .
Intra-tumoural heterogeneity may also be non-genetic and intrinsic to the hierarchical organization of some tumours, in which a small subpopulation of cancer stem cells (CSCs) may be responsible for long-term tumorigenicity [42] [43] [44] [45] . CSCs are thought to be chemoresistant and the main cause of also occurs [24] [25] [26] [27] [28] . Such intra-tumour and inter-tumour variability affects therapeutic responses, and hence needs to be considered in the preclinical and clinical settings. Although some engraftment-associated selection has been documented 24, 29 , PDX models of breast cancer seemingly preserve most of the genomic clonal architecture of the original patient sample and also seem to resemble patient counterparts at the Participating laboratories are affiliated with comprehensive cancer centres within which preclinical experimentation is closely associated with clinical activities. This allows for the efficient sharing of patient specimens -together with fully annotated clinical information -and facilitates the collection of tumours with unique characteristics (for example, rare types, exceptional responders and therapy-refractory cases). Currently sustained by membership fees organized by a consortium agreement, EurOPDX aims to obtain competitive infrastructural funding to further implement collaborative research projects and to formalize external access procedures to models. The consortium agreement also sets forth general rules for confidentiality and intellectual property issues to regulate activities among EurOPDX members (co-ownership of results) and between EurOPDX and potential partners, including other patient-derived xenograft (PDX) consortia and industry.
Main objectives
• To create a uniquely extensive collection of characterized PDX models. The collection consists of more than 1,500 subcutaneous and orthotopic models from more than 30 different pathologies (see TABLE 2 ). The models and their molecular annotation are currently being made publicly available through the cBioPortal, and are accessible for collaboration upon signature of a material transfer agreement. Systematic derivation of primary cultures and organoids for in vitro studies is planned.
• To provide a platform for population-scale studies to discover low-prevalence genetic alterations with clinically actionable potential; to explore mechanisms of therapeutic resistance in molecularly defined tumour subtypes; and to develop predictive biomarkers for personalized cancer treatment.
• To harmonize working practices. This entails several aspects: first, standardization of biobanking procedures, including systematic assessment of genetic identity by single nucleotide polymorphism (SNP) DNA fingerprinting. Second, the implementation of common rules for PDX expansion and archiving; discussions are ongoing to limit PDX propagation to a maximum of five passages, but exceptions will be considered for tumour types known to deteriorate after freezing-thawing steps and for models characterized by very indolent growth, for which expansions up to five passages would take exceedingly long. Third, optimization of inter-laboratory reproducibility through proof-of-concept studies by which models from the same source are tested independently. And finally, the definition of a set of minimal information to be linked to each PDX. . Many of the models are being licensed to the Jackson Laboratories for industry-scale purposes, including distribution on a fee-for-service basis.
Other major PDX initiatives
• Novartis Institutes for Biomedical Research PDX Encyclopedia (NIBR PDXE), an industry-led initiative that includes approximately 1,000 models 9 . Clinical, pathological and PDX-level data from this collection are currently being incorporated into PRoXe 165 .
recurrence and distant metastasis [46] [47] [48] . Much of the supporting evidence originates from PDX models that were directly derived from various clinical samples, including CTCs, ascites fluid and pleural effusion cells, and surgical biopsy samples [49] [50] [51] [52] [53] . PDX models have provided evidence of CSC colonization CSCs recapitulate the full characteristics of stem cells (that is, they are undifferentiated cells with limitless replicative potential, which partly self-perpetuate to maintain a tumorigenic reservoir and which partly differentiate to give rise to a diverse progeny of non-tumorigenic cells) or simply identify in metastatic sites and have also highlighted the role and importance of the surrounding tumour stroma, a niche that is known to influence CSC behaviour by cell-to-cell contacts and through the secretion of pro-tumorigenic ligands and cytokines 8, 51, 54 . An ongoing debate exists as to whether a more robust or proliferative population of 'tumour-initiating' cells selected by engraftment. To address this quandary, it will be important to compare the results of side-by-side fate-mapping experiments and transplantation assays to analyse whether the cells endowed with tumorigenic potential after transplantation also exhibit other typical stem-like properties, such as the ability to self-renew, asymmetric cell division and differentiation potential 55 .
PDX models of treatment-resistant disease.
There are primarily two ways in which PDX models can be used to interrogate primary and acquired resistance. One strategy is to derive models from patients' samples before the initiation of therapy and again at the time of treatment resistance. Alternatively, models can be developed from pretreatment tumour samples, and resistance can be recapitulated in the PDX upon iterative cycles of exposure to the drug, as previously observed in genetically engineered mouse (GEM) models 56 . Using cycles of drug exposure in pretreatment PDX models, paired analysis of PDX models of cisplatinsensitive and cisplatin-resistant testicular germ cell cancer (TGCC) proposed potential alternatives for the treatment of cisplatinrefractory TGCC, including anti-angiogenic therapy 57 and the blockade of the platelet-derived growth factor receptor-β (PDGFRβ)-AKT pathway 58 . PDX models have also proved useful in identifying mechanisms of resistance to targeted therapies in oestrogen receptor (ER)-positive breast cancer. The analysis of four hormone-resistant PDX tumours, which were obtained from two ER-positive breast cancer PDX models by continuous treatment with tamoxifen or by oophorectomymediated hormone depletion, revealed that hormone resistance was associated with various forms of deregulated ER-mediated gene transcription 33 . Taking a similar approach, PDX models of ER-positive breast cancer have been used to investigate jagged 1 (JAG1)-NOTCH4 signalling as a means for attenuating sensitivity to hormonal therapy 59 and to identify mechanisms of acquired resistance to cyclin-dependent kinase 4 (CDK4) and CDK6 blockade 60 .
Patients with advanced cancer who acquire resistance to several lines of treatment mostly present with multiple metastatic lesions that are not amenable to resection, and may harbour different resistance pathways. Generating PDX models that recapitulate such complex scenarios of therapy-resistant metastatic tumours models to test drug combinations that aim to overcome acquired resistance, generating information that could be transferred back to the donor patient for therapeutic decisions (see below). However, this opportunity might be hindered by limitations such as the low engraftment success rates for some tumour types and the disconnection between the time needed for PDX expansion and treatment (which can be long, especially for tumours with indolent growth in mice) and the rapidity of disease progression in patients.
Finally, PDXs that are established from tumours resistant to conventional therapies delivered in the neoadjuvant setting are of special interest (TABLE 1) . In triple-negative breast cancer, the establishment and molecular profiling of PDXs from residual cancer cells that persist after neoadjuvant treatment (minimal residual disease (MRD)) may lead to the identification of targetable molecular alterations in the chemotherapyresistant component of the tumour, which may mirror micro-metastases that are destined to clinically recur 68 . Despite often being limited in size due to prior exposure to cytotoxic therapy, triple-negative breast tumours from patients treated in the neoadjuvant setting engraft much more efficiently than do treatment-naive tumours (72% and 34%, respectively) (TABLE 2) . Given the high engraftment efficiency and rapid growth of PDXs from drug-tolerant MRD tissues, at least in the case of breast cancer, these models represent an unprecedented opportunity to identify genomic alterations and associated targeted therapies before tumour recurrence in patients.
Next-generation PDX models
Humanized PDX models to evaluate cancer immunotherapies. The importance of the immune system in tumour progression and treatment highlights the need for PDX models to facilitate the preclinical assessment of cancer immune therapies 69 . However, to avoid immune rejection of xenotransplants by the host, PDX models are primarily generated by transplanting tumour fragments into immunodeficient mice. The absence of many components of the immune system in these mice, and the loss of endogenous human immune cells upon propagation of the human tumour tissue over multiple passages 70, 71 , limit the utility of such models to explore the role of the immune system in tumour progression and to test novel immune-based therapies 72 . Humanized mice (also known as human haemato-lymphoid chimeric mice and human immune system (HIS) models) has become feasible for several tumours (TABLE 1) . For example, the analysis of biopsy specimens and corresponding PDXs from different drug-resistant metastases in patients with melanoma who had been treated with a BRAF inhibitor resulted in the identification of multiple resistance mechanisms both within individual lesions and among separate samples from the same patient 35, 38 . The resistance mechanisms identified in PDXs were also found in the original patient samples 35 , and clinically resistant tumours were also treatmentrefractory when grown as PDXs 38 . These studies provide proof of principle for the heterogeneous nature of acquired resistance in individual patients with melanoma and further attest to the ability of PDX models to predict clinical outcomes. Similar results have been observed in lung adenocarcinomas 61 . Although PDXs generally retain drug-sensitivity profiles that are similar to those of the corresponding patient tumour 30, 38, 62, 63 , PDX models derived from treatment-resistant tumours can become sensitive again upon xenografting, owing to the effect of the so-called 'drug holiday' in which treatment is discontinued after tumour implantation to facilitate engraftment. Some resistance mechanisms are thus reversible in the absence of drug, as shown for melanoma 64, 65 and lung adenocarcinoma 66 . This suggests that treatment-resistant PDXs should be exposed to continuous treatment immediately after implantation, although this is a cost-and labour-intensive approach. However, uninterrupted therapy might also result in the further selection of a subpopulation of tumour cells, resulting in a loss of intra-tumour heterogeneity and genetic variation in the PDX tumours compared with the original tumours.
In response to the need for more sophisticated models, several groups (for example, see REF. 67 ) have developed protocols and networks to generate clinical trial-associated xenografts (CTAXs) (TABLE 1) . These advanced PDX models are currently being derived from image-guided biopsy samples taken at different time points during disease progression and following new lines of treatment in the context of clinical trials. Such models will be extremely valuable in evaluating how the molecular evolution of advanced tumours is associated with innate or acquired drug resistance, and will be important for studying the tumour heterogeneity and clonal selection that results from drug treatment. In principle, CTAXs may also serve as personalized cancer are immunocompromised mice in which selected immune components have been introduced to generate a competent human immune system with different degrees of immune reconstitution. One methodology for the generation of humanized mice involves the transplantation of total peripheral blood from healthy human donors or patients (peripheral blood lymphocyte used for cost-effective short-term testing of novel immune therapeutics and for assessing short-term adverse effects.
Alternatively, HIS mice can be generated through the transplantation of CD34-positive human haematopoietic stem cells (HSCs) or precursor cells isolated from umbilical cord blood, bone marrow and peripheral blood, either alone or in combination with additional human immune tissues (bone ossicles or human thymic tissue) 76 into immunodeficient mice (FIG. 1) . Compared with PBL-and TIL-derived models, transplantation with HSCs results in a more complete haematopoietic reconstitution, as HSCs give rise to various lineages of human blood cells throughout the life of the animal. Methods for transplantation depend on the source of HSCs, the co-transplantation of immune tissues, the mouse strain and the age of the recipient mice [75] [76] [77] [78] . In order to avoid the immune reactions caused by human leukocyte antigen (HLA) mismatch, the ideal source of HSCs is the same patient from whom the PDX has been established. However, isolating HSCs from cancer patients may prove daunting: on the one hand, bone marrow biopsies are difficult in debilitated individuals; on the other hand, growth factor-stimulated bone marrow mobilization for HSC collection from peripheral blood might foster tumour progression 79 . Moreover, even when applicable, the low yield of HSCs obtainable from cancer patients severely limits the number of mice than can be humanized. An attractive alternative is the in vitro expansion of HSCs 80 , although this procedure could introduce biological perturbations that affect stemness and differentiation potential.
Whereas various strains of immunodeficient mice are used to transplant solid tumour tissue, not all of these strains are suitable for generating HIS models. The survival of human immune cells is highly dependent on the compatibility of the 'do-not-eat-me' signals (CD47-signal-regulatory protein-α (SIRPα)) on phagocytes in the host 81 . The most commonly used mice to generate compatible HIS models are those derived from the non-obese-diabetic (NOD)-severe combined immune deficiency (SCID)-interleukin-2 receptor common γ-chain (IL2-Rγ)-deficient (NSG; also known as NOD.Cg-Prkdc scid Il2rg tm1Wjll /SzJ) strain and the NOD/Sci-SCID/IL-2Rγ strain (NOG; also known as NOD-Cg-Prkdc scid Il2rg tm1Sug /JicTac). Substantial efforts are thus being made to develop novel GEM (PBL) models) or, in particular applications, the infusion of tumour-infiltrating lymphocytes (TILs) (FIG. 1) . Although these procedures are known to cause severe graftversus-host disease (GvHD) beginning 2-5 weeks after injection 73, 74 , seriously limiting the useful investigative time window of these models and the translational value of these studies 75 , PBL and TIL mice can be Nature Reviews | Cancer . Mice with a NOD (non-obese diabetic) background have functionally deficient NK cells. SCID (severe combined immunodeficiency) is a loss-of-function mutation that affects DNAdependent protein kinase (DNA-PK), a DNA repair enzyme involved in V(D)J recombination during T cell and B cell development. As a consequence, SCID mice have reduced levels of T cells and B cells. Inactivation of the interleukin-2 (IL-2) receptor γ-chain leads to impaired T cell and B cell development and prevents the generation of NK cells. Recombination-activating gene 1 (RAG1) is necessary for V(D) J recombination; thus, RAG1 inactivating mutations affect T cell and B cell development. All these different strains show subtle differences to support the engraftment of functional human immune cells 173 . Injection of human CD34-positive HSCs into these mice leads to the generation of major histocompatibility complex (MHC)-restricted T cells and B cells, as well as to limited amounts of monocytes, macrophages, neutrophils and dendritic cells. In addition, these mouse strains have been improved by genetic modifications for the production of a variety of human cytokines that stimulate the differentiation of additional haemato poietic lineages. For example, strains such as NOG-GM3 (which expresses human IL-3 and granulocyte-macrophage colony-stimulating factor (GM-CSF; also known as CSF2) 175 , NSG-SGM3 (which expresses human IL-3, GM-CSF and SCF (also known as KIT ligand)) 176 and MISTRG (which expresses IL-3, GM-CSF, macrophage CSF (M-CSF; also known as CSF1), signal regulatory protein-α (SIRPα) and thrombopoietin (THPO)) 177 produce increased numbers of human myeloid and mast cells, regulatory T cells and NK cells (see Supplementary information S1 (table) ). PDXs, patient-derived xenografts.
strains that not only express human-specific do-not-eat-me signals but also express human-specific cytokines or HLAs. These mouse strains differ upon transplantation in durability and quality of engraftment of the human immune system 78 . Some key examples of how humanized models are currently evolving to support PDX transplantation towards application in the immune-oncology space are presented as online supplementary information (see Supplementary information S1 (table)).
Modelling metastatic disease. Subcutaneous transplantation usually fails to reproduce the organ-specific tropism of distant metastases that is observed in patients. Therefore, models of metastatic disease are typically generated through orthotopic procedures. These include the transplantation of fragments of the primary tumour into the same location in the mouse, which is usually followed by the development of spontaneous metastases, or the direct transfer of metastatic lesions into the same organ in the host (TABLE 1) . Patient-derived orthotopic xenografts (PDOXs; also known as orthoxenografts) of primary tumours can reproducibly lead to local invasive growth and metastases, often identical to those observed in the patient [82] [83] [84] . PDOX models for most cancer indications have typically been developed from surgical specimens. More recently, however, they have been successfully derived from biopsy samples, despite the limited quantity and quality of tissue available 85 .
Advantages of orthotopic models include the ability to investigate tumourhost interactions at the relevant site of primary and secondary tumour growth, the development of patient-like metastases, the ability to interrogate site-specific dependence of therapy, and the potential to conduct clinically relevant studies, such as monitoring the effects of adjuvant therapy on occult metastases (TABLE 1) . Nevertheless, orthotopic models remain relatively rare, probably owing to the non-trivial microsurgical procedures that are required for organ-specific transplantation. Furthermore, the incorporation of clinically relevant imaging modalities and appropriate in vivo imaging probes is necessary to visualize tumour orthotopic implants and metastatic progression in deep tissues and to ensure timely therapeutic intervention when animals develop disease symptoms 86 . PDOX models of breast cancer are particularly amenable for modelling metastasis. They primarily rely on CTC-derived PDX models. As mentioned above, a step forwards for minimally invasive tumour sampling is the isolation and characterization of CTCs, detected at low concentrations in the peripheral blood of patients with different solid tumours 40 . Although the role of CTCs in metastasis development is still uncertain 40 , their levels ostensibly correlate with patient survival and response to therapy [94] [95] [96] . These features mean that CTCs are promising tools to monitor cancer burden and drug susceptibility in metastatic and late-stage disease, when repetitive biopsies are not indicated. Technological advances now allow the isolation of viable CTCs, which maintain tumorigenicity when xenografted into immunocompromised mice [97] [98] [99] (TABLE 1) .
Several reports have demonstrated the feasibility of establishing CTC-derived PDX models by directly injecting freshly isolated and enriched CTCs from patients with different cancers into immunocompromised mice. Using various CTC-capture techniques (such as epithelial cell adhesion molecule (EPCAM) or cytokeratin-based selection of cancer cells derived from epithelial tissues or microfluidic-based leukocyte depletion 100, 101 ), CTC-derived xenografts are now practicable for breast cancer 97 , prostate cancer 102 , gastric cancer 103 , small-cell lung cancer (SCLC) 98 and melanoma 91 . Moreover, it has also been shown that ex vivo cultivated and fully molecularly characterized breast 104 and colorectal 105 CTCs maintain their tumorigenic potential. Notably, both freshly isolated CTCs and CTC-derived PDXs genetically and histologically mirror the original tumour and retain analogous drug sensitivities 91, 97, 98, 100, [102] [103] [104] [105] . For example, PDXs that are established from chemotherapy-naive circulating SCLC cells recapitulate donor patients' response to both platinum and etoposide 98 . In patients with ER-positive breast cancer, CTCs have also proved to be a useful model to study the genetic evolution of the tumour and to identify novel drug susceptibilities 104 . Although technically challenging, the use of CTC-derived PDX models opens new possibilities for translational research. In addition to being a source of information regarding disease prognosis 106 , tumour heterogeneity 107, 108 , evolution 109 and dissemination 110, 111 , CTC-derived PDXs hold promise for precision medicine applications (TABLE 1) . For example, CTCs from women with treatment-refractory ER-positive breast tumours have been recently analysed to investigate the functional and phenotypic consequences of prolonged anti-hormonal therapies, and xenografts from such CTCs mammary fat pad injection of primary tumour samples, which successfully recapitulates the entire metastatic process from the appropriate primary anatomical site 8, 87 . PDOX models of brain metastases and primary brain tumours are challenging. To prevent the default seeding of intravenously injected tumour cells in the lung and to ensure colonization of the central nervous system, intra-cardiac left ventricular inoculation of tumour cells is required 88 . Cells may also be implanted intracranially to overcome the bloodbrain barrier 89 . Orthotopic homing and the metastatic potential of cancer cells can be boosted by genetic modification; for example, colorectal cancer PDX cells engineered to express C-C motif chemokine receptor 9 (CCR9) efficiently localize to the mouse colon after tail-vein injection, attracted by the abundance of the CCR9 ligand C-C motif chemokine ligand 25 (CCL25) in the intestine, and then spontaneously metastasize to the liver 90 . Genetic manipulation is useful to develop models of spontaneous metastasis for mechanistic studies in vivo; however, the introduction of exogenous molecules to patient-derived material may affect some properties of the original tumour, thus reducing translational relevance.
Whether PDOX models more accurately recapitulate clinical response to anticancer drugs compared with conventional subcutaneous PDX models remains to be established. One report showed that the antitumoural effects of a microtubulestabilizing drug on PDX models of brain metastases from non-small-cell lung cancer were different in orthotopic versus subcutaneous implants 85 , but results remain anecdotal. It is conceivable that therapies that target components of the tumour microenvironment, such as endothelial cells and immune cells, would be better evaluated in an orthotopic context. Conversely, the therapeutic response of 'oncogene-addicted tumours' , which intrinsically rely on activating mutations for their growth and survival, is likely to be less dependent on anatomical location and more influenced by the underlying cancer genetic makeup. Indeed, despite their heterotopic location, subcutaneous PDXs from BRAF-mutant melanoma 9, 91 and HER2 (also known as ERBB2)-amplified colorectal cancer 6, 92, 93 mimic the therapeutic response observed in patients. Sharing results from different experimental models within the EurOPDX consortium will allow us to shed some light on this important question.
have been used to design new therapies to overcome resistance 112 . Similarly, the next-generation sequencing of tumours, complemented with genomic analysis of CTCs and CTC-derived PDX mouse models, has proved to be a powerful platform for developing precision medicine strategies in patients with melanoma 91 . This approach has, in specific cases, facilitated the clinical implementation of alternative therapeutic strategies informed by the preclinical models 91 .
PDXs for clinical decision-making PDX population xenopatient trials. Across tumours of the same origin, genetic lesions that sustain tumorigenesis (and that therefore associate with response to targeted drugs) often involve many different oncogenes, each of which is mutated at a low frequency 113 . Furthermore, genotype-based prediction of drug response is not unequivocal. Despite harbouring the genetic lesion that is known to correlate with drug response, many tumours do not regress owing to the presence of signals that compensate for target inhibition 114 . Collectively, this information treatment were identified as mechanisms of tumour adaptation to EGFR family 117, 118 or MEK 119 inhibition in colorectal cancer. The flexibility of PDXs also enabled preclinical testing of drug combinations in models displaying some of these resistance traits, with a permutation capability that was clearly beyond the number of testable hypotheses in humans (FIG. 2) .
An analogous population-based drug screen has recently been carried out in more than 1,000 PDX models representing a wide range of solid cancers (the 'PDX Encyclopaedia') 9 . Some genetic hypotheses and biomarkers of drug sensitivity, which emerged from cultured cancer cell lines, were successfully validated in this large panel of PDX models (FIG. 2) . Notably, experiments in PDXs also enabled the identification of therapeutic candidates that in vitro model systems failed to capture 9 .
In all these studies, responses obtained in mice were highly consistent with responses in patients. For example, the distribution of tumour regression, disease stabilization and progression in colorectal cancer indicates that the genetic selection of tumours for the application of targeted therapies requires representative study populations and suitable pharmacogenomic platforms.
Provided that they are generated in high numbers and extensively characterized at the molecular level, PDXs can act as a powerful resource for large-scale genotype-response correlations and therapeutic studies in genetically defined tumour subsets. Several recent studies testify to this potential; in late-stage colorectal cancer, for example, a systematic assessment of response to antibodies targeting epidermal growth factor receptor (EGFR) using PDX models ('xenopatients') derived from hundreds of individual tumours was coupled to candidate-gene or whole-exome sequencing analyses. Through this effort, several genetic determinants of resistance to EGFR blockade were discovered, including amplifications or mutations in genes encoding druggable kinases 6, 7, 115, 116 . Similarly, more dynamic features such as expression changes in pro-survival genes and the activation of compensatory feedback loops during Nature Reviews | Cancer ) now allow population-based studies to be carried out, which better mimic the inter-tumour heterogeneity that is seen in patients and are more predictive of clinical efficacy than conventional xenografts of immortalized cancer cell lines. PDX molecular characterization and correlation with therapeutic response also facilitates biomarker discovery, as well as the identification of primary (and acquired) resistance mechanisms. These studies can lead to new hypotheses and support the initiation of new clinical trials. b | For some cancer types for which avatar models can be developed, co-clinical avatar studies allow for simultaneous drug testing in mice and patients for real-time adaptive therapeutic decisions. c | In the 'biofacsimile' or 'proxy' study format, integrative systemsbased bioinformatics analysis can be used to pinpoint the best-matched PDX for a given patient from a collection of molecularly profiled models. PDXassociated information is then leveraged to instruct clinical treatment options and/or to derive prognostic indicators. NGS, next-generation sequencing. xenopatients receiving EGFR antibodies was similar to that found in the clinic, and treatment-refractory tumour grafts were enriched for known genetic predictors of therapeutic resistance in patients 6 (TABLE 3) ; moreover, in analogy with clinical studies 120 , the addition of an EGFR small-molecule inhibitor to the EGFR antibody increased tumour regression 118 . Similarly, PDXs from BRAF-mutant melanomas underwent substantial shrinkage when treated with BRAF inhibitors, a response that was further magnified -as in patients -by the addition of a MEK inhibitor 9, 121 . PDX platforms have recently been used for the systematic identification of cancer vulnerabilities through RNA interference-based genetic screens in tumour grafts, which have revealed new oncogenic drivers in melanoma 122 and pancreatic tumours 123 . PDX population trials may be highly informative, but they are also expensive and technically cumbersome, and the trade-off between sufficient sample size to ensure adequate coverage of inter-patient heterogeneity and experimental feasibility requires careful study design. To reduce the number of animal replicates while preserving statistical power, reproducibility studies have been conducted to compare response calls made on a single mouse with majority responses in reference cohorts composed of many animals. Thus, a strong concordance between single-mouse responses and majority responses has been found, with a prediction accuracy varying from 75%
124 to 95% 9 . Accordingly, 'one the patients and the preclinical model will help to define the mechanism of action of a given drug, as well as biomarkers of response. Originally implemented with GEM models, the co-clinical trial concept has been expanded to include PDX models ('avatars'), which are generated from cancer patients enrolled in clinical trials and, in parallel, treated with the same drug or drugs that the patient is receiving 10 (FIG. 2) .
In general, these studies aim to develop a PDX model from newly diagnosed patients and use it to explore therapies that can be administered to the patient at the time of disease progression. Ongoing trials cover different tumour settings, including sarcomas (NCT02720796) 135 , head and neck carcinomas (NCT02752932) 136 , ovarian cancer (NCT02312245) 137 and pancreatic cancer (NCT02795650) 138 . Although a cogent argument exists for implementing avatar trials, and several case reports have provided data to support the concept [139] [140] [141] , the logistical difficulties and technical hurdles are likely to limit the broad applicability of this approach (see above).
PDX models in biomarker development.
The validation of mechanisms that link specific biomarkers to treatment efficacy will have direct clinical effects, allowing patient stratification for tailored treatment protocols. Large-scale PDX trial formats, such as the PDX Encyclopaedia 9 mentioned above, represent a more accurate approach to identify predictive biomarkers compared with the use of cell lines (TABLE 1) .
animal per model per treatment' (1 × 1 × 1) approaches have recently been advocated 9, 125 . Alternative strategies to reduce experimental burden could rely on step-wise approaches, in which large-scale pharmacogenomic screens are carried out using less laborious formats (such as cancer cell lines) followed by in vivo validation in selected, molecularly relevant PDX models. In this regard, it is noteworthy that patient-derived material from human tumours, such as colorectal, pancreas and prostate cancers [126] [127] [128] [129] [130] [131] [132] , can be grown and nearly indefinitely expanded as threedimensional (3D) organoids. These can be easily transplanted to establish PDXs, and vice versa, and are amenable to drug screens in a semi-high-throughput manner 130 . Albeit more difficult to establish and propagate, two-dimensional (2D) primary cultures of dissociated cancer cells from both patient samples and PDXs are also being attempted with a similar rationale and objectives 133 . In this vein, a platform for drug testing in short-term cultured breast cancer cells from PDXs has recently been developed and shown to predict in vivo drug response 29 .
PDX co-clinical avatar trials. The term co-clinical trial refers to simultaneous clinical and preclinical trials with anticancer agents in patients with a tumour type of a defined genetic makeup and a mouse model with similar genetic abnormalities 134 . The underpinning idea is that the comparison of responses between A transcriptional profiling study on 85 PDX models of nine different cancer types treated with nine separate cancer drugs identified 1,578 genes, the expression of which correlated with sensitivity to at least one drug; 333 of these genes showed significant association with sensitivity to two or more drugs, and 32 genes predicted response to six or seven drugs 142 . This type of study provides an initial set of biomarkers that require further evaluation in clinical material to determine translatability into a clinically useful assay.
Epigenetic biomarkers, such as DNA methylation, can also be assessed in PDXs as possible response predictors. A study that included 28 glioblastoma PDOXs showed that the poly(ADP-ribose) polymerase (PARP) inhibitor veliparib significantly enhances the efficacy of temozolomide (TMZ) chemotherapy only in models with O-6-methylguanine-DNA methyltransferase (MGMT) promoter hyper-methylation 143 . On the basis of these data, MGMT promoter hyper-methylation was included as an eligibility criterion for TMZ and veliparib combination treatment in an ongoing phase II/III glioblastoma clinical trial (NCT02152982) 144 . Determinants of therapeutic sensitivity can be identified at the protein level using pathway analysis in PDXs: a proteomic survey of 20 PDX models of glioblastoma and their parental tumours identified a subset of cases with comparable proteomic profiles displaying high levels of expression and phosphorylation of EGFR and its downstream signalling proteins 145 . The expression and phosphorylation status of EGFR and downstream targets might be used as a predictive biomarker of response to EGFR inhibition in preclinical trials and, if successful, included in future clinical trials aiming to inhibit EGFR signalling in patients with glioblastoma.
PDX models are also useful for the preclinical identification of metabolic biomarkers using magnetic resonance spectroscopy (MRS). This technique has recently been used to demonstrate differences in metabolic characteristics between molecular subtypes of breast cancer 146, 147 . Elevated phosphocholine levels and low glycerophosphocholine levels have been proposed to be metabolic markers of aggressive disease in breast cancer based on in vitro studies 148 . However, MRS on intact tissue from PDX models of poor-prognosis basal-like breast cancer displays an inverted metabolic profile, with high glycerophosphocholine concentration rather than high molecular levels; retaining, to the highest possible extent, the functional, phenotypic and genotypic characteristics of human tumours; faithfully predicting response to therapies, and recapitulating mechanisms of innate and acquired resistance; and allowing for experimental flexibility.
Although PDXs fulfil several of these criteria and can be further improved to meet additional requirements, certain inherent limitations remain difficult to address. A major obstacle is the necessity of using immunocompromised mice to circumvent xenograft rejection. This requirement hampers the use of current PDX models to assess immunotherapeutics. Although emerging humanization procedures are now expected to overcome some of the most important concerns (see Supplementary information S1 (table)), issues still remain with the incorporation of particular immune cell types, immune responses and lymphoid structures into these humanized models and with the eradication of xenogeneic GvHD. It is expected that the development of novel immune-deficient mice will take advantage of emerging technologies based on engineered nuclease enzymes for genome editing (such as transcription activator-like effector nuclease (TALEN) and CRISPR-Cas9). These modifications will include the replacement or introduction of combinations of human-specific cytokine receptors and adhesion molecules, as well as more comprehensive sets of HLA class I and HLA class II molecules.
As mentioned above, serial passaging of tumours leads to the substitution of human stroma by murine components, and mouse-derived cytokines and growth factors in some cases do not crossreact with receptors that are expressed by human (cancer) cells [159] [160] [161] [162] . This makes the contribution of the tumour micro environment to drug response difficult to assess in PDXs. Moreover, the lack of a species-compatible tumour stroma complicates the identification of pharmacodynamic markers of target inactivation for drugs that intercept cancer-related microenvironmental processes, such as angiogenesis and inflammation. Although mouse humanization procedures seek to reconstitute the human immune system, the replacement of stromal elements such as endothelial cells and fibroblasts with their human counterparts is currently daunting, if not unfeasible.
PDX-based efforts for cancer precision medicine also require adequate logistics, from proper archival phosphocholine concentration 146, 147 . These observations suggest that proper tumour architecture, as maintained in PDXs, influences choline metabolism. Accordingly, a strong correlation between PDX models and clinical material was observed in the expression of genes that are involved in key metabolic pathways 146 . MRS technology also holds potential for in vivo non-invasive detection of metabolic biomarkers through tailored techniques such as 31P MRS or hyperpolarized 13C MRS 149, 150 . Recently, a proof-of-principle study demonstrated the ability of in vivo MRS to distinguish basal-like from luminal-like breast cancer PDXs non-invasively using 31P MRS imaging 151 . For some cancer types, the ability of tumours to successfully engraft in mice can be considered per se as a surrogate biomarker of risk for disease progression. For example, in mammary tumours, the ability to generate stable tumour grafts significantly predicted reduced survival 8, 152 , and gene expression signatures associated with successful PDX engraftment correlated with worse survival outcome when tested in prognostically annotated data sets of triple-negative breast cancer 153 . Similarly, tumour grafts of pancreatic ductal adenocarcinoma displayed higher expression of metastasisassociated genes compared with samples that failed engraftment, and patient donors of successfully engrafted tumours had shorter survival 154 . It is now well established that human tumour stromal cells are replaced by mouse counterparts following engraftment 155 . As a consequence of this substitution, species-specific RNA sequencing-based expression profiling of PDXs offers a unique opportunity to distinguish mouse stroma-derived transcripts from human cancer cell-derived transcripts without the need to physically separate the two components before RNA extraction. Such analyses led to the identification of stromalassociated transcriptional signatures in colorectal cancer that are associated with poor prognosis and treatment resistance 156 . The negative prognostic significance of tumour stromal transcriptional signatures and their value for therapeutic decision-making and patient follow-up have also been described in other reports 157, 158 .
Challenges and opportunities
Ideal animal models for preclinical experimentation in oncology should fulfil several criteria: reflecting the diversity of cancer patients at the epidemiological and biobanking to continuous propagation of live biospecimens, intensive animal experimentation and systematic integration of therapeutic results with high-content molecular annotation. The perception of this complexity and the awareness that resource sustainability cannot be maintained by individual academic laboratories have fuelled initiatives for creating and implementing shared large-scale PDX platforms, including the European EurOPDX resource, the US National Cancer Institute (NCI) repository of patient-derived models, the Public Repository of Xenografts (PRoXe), the Children's Oncology Group (COG) cell culture and xenograft repository, and the Pediatric Preclinical Testing Consortium (PPTC)
.
When dealing with such large multiinstitutional platforms, standardized methodological procedures should be carried out to ensure reproducibility and to streamline readouts so that they are interpretable across different laboratories
. Further, therapeutic outcomes should be univocally deciphered and stringently interpreted. Retardation of tumour growth during therapy typically results in tumours that are smaller than controls at end point, but larger than they were before starting treatment; although this may well suggest that the therapy is biologically active (because it affects cancer cell proliferation), it is not an indication that the therapy is clinically effective; indeed, this kind of response would be clinically defined as 'disease progression' or, at best, 'disease stabilization' . In the EurOPDX experience, even manifest effects of tumour growth inhibition -as observed, for example, after blockade of MEK in PDXs of KRAS-mutant colorectal cancer 125 -did not translate into clinical benefit when analogous therapies were applied to patients 163 . By contrast, overt regression in PDXs predicted positive results in the clinic: the finding that an antibody and small molecule combination against HER2 induced massive regressions in HER2-amplified colorectal tumour grafts 6, 117 has recently been translated into a successful clinical trial, with the vast majority of patients achieving tumour shrinkage when treated with the same regimen 93 . It has also become increasingly clear that the use of quantitative metrics to classify response (equivalent to clinical Response Evaluation Criteria in Solid Tumours (RECIST)) should be implemented to more precisely assess therapeutic effects in PDX trials. Modified RECIST criteria for mouse xenograft applications have recently been described 9 . 'Best response' is defined as interoperable standards for normalization, correction and retrieval of complex data sets. The issue of big data collection, harmonization and storage is particularly important when working with large PDX collections, in which one original tumour from a single patient gives rise, upon serial passages, to many descendants that expand at an exponential rate
. In EurOPDX, efforts are ongoing to aggregate cancer genomic profiles obtained through different technologies in different laboratories and to implement a user-friendly, open-source portal that showcases the molecular characteristics of the participating collections
. Importantly, besides the detection of individual variants with clinically actionable potential, multi-dimensional molecular information from existing PDX models can be subjected to systems-based bioinformatics analysis to extract algorithms that identify key biological parameters 164 . Preliminary evidence suggests that such algorithms can the minimum value of percentage tumour volume change, compared with tumour volume at baseline, for treatment durations equal to or longer than 10 days, and 'best average response' is the minimum value of the mean percentage of tumour volume change, as measured at each evaluation time point along treatment, compared with baseline 9 . Such definitions, coupled with specific tumour volume cut-offs, have been applied to categorize complete response, partial response, stable disease and progressive disease in tumour-bearing mice. These modified RECIST criteria capture response kinetics, robustness and durability, and thus improve the ability of preclinical studies to accurately predict patient outcome.
Extended and detailed molecular annotation is a prerequisite for precision oncology paradigms. However, the accumulation of multiple layers of genomic information requires the development of computational systems with common or
Box 2 | Data management and integration
By combining the flexibility of preclinical analysis with the instructive value of population-based studies, patient-derived xenografts (PDXs) offer unprecedented opportunities for drawing statistically robust correlations between genetic or functional traits and sensitivity to anticancer drugs. However, the advantages of high-throughput studies with PDX-based approaches may become major hurdles when dealing with large-scale data management, analysis and utilization. The deployment of PDX models for translational studies often requires their stratification into existing predictive or prognostic molecular classes and subgroups as derived on tumours from patients. The portability of the stratification criteria from human to mice, and vice versa, is not trivial, owing to multiple sources of biological and genomic variation, which may be introduced in the process of engrafting and propagating patient tumour material into murine hosts.
Data management issues
Data complexity and dynamics. The representation of cancer data in classical oncogenomic portals is normally static: the results obtained by analysing such public resources are not fed back to refine, update or complement the original information. The possibility to incrementally stratify and integrate multiple layers of information generated from the same original sample by diverse laboratories at different times represents one of the key added values of PDX-based approaches. This implies the need for further dimensions of complexity to interrogate an almost infinite number of variables and to implement decision-making algorithms in case of data inconsistency across experiments 166 .
Data normalization and annotations. The joint utilization of human and PDX data requires the standardization of sample metadata such as clinical and molecular ontologies. Through this effort, data derived from different experiments, technologies and platforms can be normalized against common categories and used to interrogate samples with integrative queries exploring heterogeneous data domains.
Data analysis issues
Population selection bias. Owing to the different engraftment efficacies inherent to each tumour sample, the population of xenografts might not recapitulate the full distribution of tumour phenotypic or molecular variables observed in patients. Any prior-dependent statistical models should be adapted to the new distribution of subclasses within the PDX population. This implies the necessity to identify the missing or underrepresented subgroups through analytical investigation of multidimensional parameters (genomics, transcriptomics, histopathology, and so on).
Loss of human immune and stromal cells. Although both stromal and immune components are replaced over time by murine analogues, the haematopoietic elements show important differences in their spatial distribution 167 or may be missing overall 156, 168 . This affects the signal received from molecular profiling, and could require the application of specific algorithms for signal correction to avoid or reduce artefacts and biases 156, 169 .
be subsequently used to identify one or more 'biofacsimile' or 'proxy' PDX models for individual patients, and PDX-associated information may be leveraged to instruct treatment options and/or to derive predictive indicators in the clinic 164 (FIG. 2) .
All these considerations underscore the opportunities offered by PDX models to illuminate new angles of translational cancer research, but they also put forward the challenges that are intrinsic to this approach, and the need for finding new ways to maximize PDX potential. Industry-led PDX ventures rely on common and extensively tested operating procedures, backed by considerable funding, which ensures scalable, homogeneous and reproducible experimental schemes; however, pharmaceutical initiatives are typically bound to preclinical testing of proprietary compounds and may face obstacles in publishing results, especially when data relate to sensitive commercial or patenting issues. Conversely, owing to their multi-institutional nature, scholarly consortia usually suffer from heterogeneous characterization of their PDX collections, a flaw that is hardly corrected by the relatively limited resources provided by government or charity grants; however, PDX academic efforts enjoy flexibility in drug testing and unfettered scientific reporting (including reporting of negative results, which avoids the duplication of effort and reduces costs). As EurOPDX members working in academia, we share with our colleagues of PRoXe the concern that "academic centers are ill suited to bear the burden of housing, expanding, archiving, characterizing, and disseminating PDXs to investigators (academic and industrial) across the world" (REF. 165 ). Meanwhile, we believe that joining forces, incorporating models, coordinating methodologies, and improving the public shareability and visibility of molecular data in an academicoriented rather than in an industry-scale format are viable objectives that will foster not only a stronger collaborative spirit in cancer medicine, but also a change of mind-set within institutional authorities and industrial stakeholders. EurOPDX started as a crowd-funded initiative of scientists with common goals, complementary skills and similar needs, and is now growing in a more structured manner thanks to enterprise-wide development plans. Ultimately, we envision a virtuous circle in which new knowledge from bottom-up efforts such as ours and others will inform clinical decision making, which in turn will orient public and private financial interests to secure further sustainability of PDX-based activities. Successful examples in other contexts of biomedical research, such as TRANSAUTOPHAGY (see Further information; a European consortium for multidisciplinary research and translation of knowledge on autophagy) and GENiE (see Further information; a network of scientists using Caenorhabditis elegans as a model organism), bode well to achieve this ambition.
